Invesco's stake is negligible and unchanged in any material way. No action warranted; the filing is routine.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 11 $6.28entry
- T+1 · 5d ago −0.80%α −0.44% · $6.23
- T+3 · todayOpen
- T+5 · tomorrow Pending
- T+20 · in 23d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Invesco Ltd. filed an amendment to its Schedule 13G for Phathom Pharmaceuticals, reporting beneficial ownership of 30,562 shares as of September 30, 2026, down from 30,223 shares in the prior filing. The stake remains well below 5% and represents a negligible change, indicating routine portfolio adjustment rather than a material shift in conviction.
Key Financial Metrics
Key Facts
- Invesco Ltd. reported beneficial ownership of 30,562 shares of Phathom Pharmaceuticals as of September 30, 2026.
- The prior filing (July 2026) reported 30,223 shares; the increase is 339 shares, or approximately 1.1%.
- The stake represents 0.0% of shares outstanding per the filing.
- Invesco disclaims beneficial ownership of shares held for clients and certifies passive intent under Rule 13d-1(b).
Financial Impact
Stake value approximately $44,000 based on market cap of $427M and 0.0% ownership; change is immaterial.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000914208-26-000448 |
| Document: 0000914208-26-000448-index.html | 0000914208-26-000448 |
| Document: 0000914208-26-000448.txt | 0000914208-26-000448 |
Track record
16 reports on PHAT
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +36.43% at T+60 after the Jul 30, 2026 report. 3 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Viewing Entry $6.28 Now $5.88 −6.37% settles Nov 18
- Nov 2, 202614d ago SC 13D/A Neutral 3/10 Entry $5.74 to $5.45 Now $5.88 +2.44% ▼ −5.14% −4.55% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 5/10 Entry $6.22 to $5.08 Now $5.88 −5.47% ▼ −18.33% −13.60% vs SPY
- Oct 26, 202621d ago 8-K Bearish 5/10 Entry $5.94 to $5.74 Now $5.88 +1.01% ▲ +3.37% +2.11% vs SPY
- Oct 23, 202624d ago 8-K Bearish 6/10 Entry $5.94 to $5.74 Now $5.88 +1.01% ▲ +3.37% +2.11% vs SPY
- Oct 19, 202628d ago Press Release Neutral 1/10 Entry $7.01 Now $5.88 −16.12% No price data
- Sep 29, 20266w ago 8-K Neutral 4/10 Entry $7.30 to $6.81 Now $5.88 −19.45% ▼ −6.71% −8.63% vs SPY
- Jul 30, 202615w ago 8-K Mixed 5/10 No price data
- Jul 30, 202615w ago Press Release Bearish 6/10 Entry $9.03 to $8.39 Now $5.88 +34.88% ▲ +7.09% +10.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers